FDA approves first targeted therapy for metastatic bladder cancer

Alternative Medicine
FDAThe U.S. Food and Drug Administration today granted accelerated approval to Balversa (erdafitinib), a treatment for adult patients with locally advanced or metastatic bladder cancer that has a type of susceptible genetic alteration known as FGFR3 or FGFR2, and that has progressed during or following prior platinum-containing chemotherapy.

Leave a Reply

Your email address will not be published. Required fields are marked *